Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.
about
Dietary advice for the prevention of type 2 diabetes mellitus in adultsDietary advice for the prevention of type 2 diabetes mellitus in adultsStatin use in prediabetic patients: rationale and results to dateEffect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study.Sibutramine-associated adverse effects: a practical guide for its safe use.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentTrends in prevalence of diabetes among delivery hospitalizations, United States, 1993-2009.Statins: another class of antihypertensive agents?Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.Pleiotropic effects of thiazolidinediones.Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia.Incidental findings of elevated random plasma glucose in the ED as a prompt for outpatient diabetes screening: a retrospective study.Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus.Lipid-lowering agents and new onset diabetes mellitus.Metformin: diamonds are forever.Prevalence and impact of diabetes mellitus in patients with acute myocardial infarction: a 10-year experience.Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.Resveratrol attenuates type 2 diabetes mellitus by mediating mitochondrial biogenesis and lipid metabolism via Sirtuin type 1.A long-term mechanistic computational model of physiological factors driving the onset of type 2 diabetes in an individual.Prospective assessment of lower-extremity peripheral arterial disease in diabetic patients using a novel automated optical device.Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.
P2860
Q24186597-B9B646D8-BAF2-4514-AF3C-B49685AB56E8Q24241999-7EC447B1-5BBB-47C4-A270-39CF09E14935Q26786008-19E3D25C-B087-4A7F-BEE9-527C203AC8F3Q34574001-ECA641B3-15B8-420C-B655-3D3060D673B1Q34585304-26635DC3-72A5-490C-8EFC-4DDD1D038225Q35029623-D9F83642-C816-4505-BAE0-C838BE9B813EQ35922762-7C5135CB-E22A-4A46-87AD-3B539FA1D597Q36411099-28FB4C41-278B-43A8-9172-14B69E9DE2EAQ36480076-9B815254-E978-4936-B8BB-DBA387E04452Q36653658-E4B3D47E-7972-4FFE-AA99-C7DB487CF7F8Q36709546-573D3BE7-FE43-4F14-AF61-B00E08A4D2FAQ37000746-2ABBCCC3-1C45-41C8-80ED-71EEECBA6739Q37142044-A0307068-7385-4D29-A7C4-E2817B195B4EQ37417770-D4898D33-E820-4500-B1C7-44AD8FF4B45DQ37449520-FB7E3A3A-A13C-4BC7-8A61-3F519ACC7AA8Q37831911-61EDF439-F8B2-4E00-90D1-ADD3C4D27AE0Q43058605-64828BC3-B67A-4259-8AF8-8FECFDFA62C6Q43292535-4BC06356-BCF8-4B5F-B1A4-FB67C0E45C97Q44986493-1315FAB4-D342-44CA-A648-5927B6D137B6Q46691040-D2088C9E-3DFB-4C69-B23C-4E776F28F10CQ47700908-8D4D9B97-4947-4CEE-AD79-9D95CB4930ABQ50000469-3C7AB44C-74B1-4694-9644-71DFB1044B07Q50859723-AA1C3D64-5251-4560-83B3-87C04C5A9378Q51366717-8DBEBFEC-0533-4E10-98F3-2F6D83F7C9D7
P2860
Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Preventing type 2 diabetes in ...... and pharmacological measures.
@ast
Preventing type 2 diabetes in ...... and pharmacological measures.
@en
type
label
Preventing type 2 diabetes in ...... and pharmacological measures.
@ast
Preventing type 2 diabetes in ...... and pharmacological measures.
@en
prefLabel
Preventing type 2 diabetes in ...... and pharmacological measures.
@ast
Preventing type 2 diabetes in ...... and pharmacological measures.
@en
P1433
P1476
Preventing type 2 diabetes in ...... e and pharmacological measures
@en
P2093
D P Mikhailidis
P304
P356
10.2174/138945006775515419
P577
2006-02-01T00:00:00Z